What is a 12-month forecast aplt

A 12-month forecast for Applied Therapeutics (APLT) is positive, with potential for continued growth and success. Here's a detailed analysis:

1. Financial Performance and Growth Rates:
   • Applied Therapeutics has shown significant revenue growth, with a year-to-date increase of 150.45%. This indicates strong market demand and operational efficiency.
   • The company's net income has also grown robustly, with a year-over-year increase of 109.8%, suggesting improved profitability.
   • However, the diluted earnings per share (EPS) has decreased by 41.29%, which could be a concern for some investors, especially considering the negative P/E ratio of -4.23.

2. Analyst Ratings and Price Targets:
   • The stock has received a consensus rating of "Buy" from analysts, with an average price target of $12.50.
   • Leerink Partners has increased its price target to $14.00, indicating confidence in the company's future performance.
   • Citigroup has also raised its price target to $11.00, further supporting the positive outlook.
3. Market Sentiment and Regulatory Milestones:
   • The stock experienced a significant surge of 70% following news that the FDA would not hold an Advisory Committee meeting for govorestat approval, which is likely to be approved by the end of November.
   • This regulatory milestone, along with the company's focus on unmet medical needs and innovative drug development, positions Applied Therapeutics well for continued growth.
4. Technical Indicators:
   • The stock's technical indicators show mixed signals. The MACD is positive at 0.07, indicating potential upward momentum. However, the RSI is at 44.8, which is neither overbought nor oversold, and the KDJ is at 7.01, suggesting the stock may be oversold.
   • The stock is trading above its 5-day, 10-day, and 20-day moving averages, which could be seen as a bullish signal. However, the 60-day, 50-day, and 120-day moving averages are lower, indicating a potential for consolidation or a pullback in the near term.

5. Institutional Activity and Price Target:
   • There has been notable institutional selling, with Logos Global Management LP cutting its holdings by 55.6%, and Perceptive Advisors LLC lessening its holdings by 5.9%.
   • Despite these sales, the stock has a strong buy rating from some analysts, and the average equity rating is currently 1.17, trading closer to a bullish pattern.

In conclusion, the 12-month forecast for Applied Therapeutics is positive, driven by strong revenue growth, favorable analyst ratings, and potential regulatory approvals. However, investors should monitor the company's diluted EPS trend and the potential impact of institutional selling on the stock's performance.